PABLO
GUISADO VASCO
PROFESOR
![Foto de PABLO](/img/uploaded/CF50829333FAB8A9FA2B4553FA8F2102.jpg)
![Foto de Hospital Universitario Marqués de Valdecilla](/img/noimage_org.png)
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Marqués de Valdecilla (6)
2023
-
Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry
Scientific Reports, Vol. 13, Núm. 1
2019
-
Safety and efficacy of prolonged use of dalbavancin in bone and joint infections
Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 5
2014
-
Hepatitis C virus-related lymphoproliferative disorders encompass a broader clinical and morphological spectrum than previously recognized: A clinicopathological study
Modern Pathology, Vol. 27, Núm. 2, pp. 281-293
-
Simplification of risk stratification for splenic marginal zone lymphoma: A point-based score for practical use
Leukemia and Lymphoma
2012
-
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases
British Journal of Haematology, Vol. 159, Núm. 2, pp. 164-171
-
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819